Author: OurCrowd

[Lifeward in PR Newswire] Oramed and Lifeward announce strategic transaction

Jan 13, 2026 |

NEW YORK, Jan. 13, 2026 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (“Oramed”) and Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward”) today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed’s proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions.  Read more...

Read More

[Axiom Space in Memesita] Axiom Space Station: New plan for faster, independent orbit

Jan 13, 2026 |

CAPE CANAVERAL, FL – Forget gradual transitions. Axiom Space is hitting the gas pedal on its plans for a fully independent commercial space station, accelerating its timeline and signaling a major shift in the future of low Earth orbit (LEO). The Houston-based company revealed a revised assembly plan aiming for a functional, free-flying habitat by late 2025 – a move that dramatically reduces reliance on the aging International Space Station (ISS) and throws down the gauntlet in the burgeoning private space station race. Read...

Read More

[Alloy Therapeutics in BusinessWire] Tahoe Therapeutics and Alloy Therapeutics to form joint venture and develop first-in-class antibody-drug conjugates for hard-to-treat cancers

Jan 13, 2026 |

BOSTON & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers. Read more...

Read More

[Polarisqb in Quantum Computing Report] Polaris Quantum Biotech study demonstrates quantum advantage over generative AI in drug discovery

Jan 12, 2026 |

Polaris Quantum Biotech (PolarisQB) has released a comparative study indicating that its Quantum-Aided Drug Design (QuADD) platform, powered by D-Wave Quantum Inc.’s annealing technology, significantly outperforms classical Generative AI in lead identification for drug discovery. The study, currently a preprint on ChemRxiv, compared QuADD to the Bond and Interaction generating Diffusion model (BInD), a representative AI-based diffusion algorithm. The findings suggest that quantum annealing can reduce the timeline for selecting pre-clinical molecular candidates from months to hours while delivering higher-quality results. Watch...

Read More